Epocrates (Nasdaq: EPOC) reported earnings on Aug. 7. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended June 30 (Q2), Epocrates beat expectations on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue contracted and GAAP earnings per share shrank to a loss.

Margins dropped across the board.

Revenue details
 Epocrates reported revenue of $26.8 million. The six analysts polled by S&P Capital IQ expected sales of $25.8 million on the same basis. GAAP reported sales were 3.7% lower than the prior-year quarter's $27.9 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at $0.03. The six earnings estimates compiled by S&P Capital IQ anticipated $0.01 per share. GAAP EPS were -$0.02 for Q2 against $0.13 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 59.2%, 570 basis points worse than the prior-year quarter. Operating margin was -5.3%, 300 basis points worse than the prior-year quarter. Net margin was -1.5%, 1,370 basis points worse than the prior-year quarter.

Looking ahead
 Next quarter's average estimate for revenue is $25.7 million. On the bottom line, the average EPS estimate is $0.01.

Next year's average estimate for revenue is $109.4 million. The average EPS estimate is $0.17.

Investor sentiment
 The stock has a five-star rating (out of five) at Motley Fool CAPS, with 33 members out of 35 rating the stock outperform, and two members rating it underperform. Among six CAPS All-Star picks (recommendations by the highest-ranked CAPS members), six give Epocrates a green thumbs-up, and give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Epocrates is hold, with an average price target of $10.00.